Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells Via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor
Open Access
- 25 December 2018
- Vol. 11 (1), 22
- https://doi.org/10.3390/cancers11010022
Abstract
Malignant gliomas are the most aggressive forms of brain tumors; whose metastasis and recurrence contribute to high rates of morbidity and mortality. Glioma stem cell-like cells are a subpopulation of tumor-initiating cells responsible for glioma tumorigenesis, metastasis, recurrence and resistance to therapy. Epidermal growth factor receptor (EGFR) has been reported to be dysregulated in most cancers, including gliomas and its functions are closely linked to initiating tumor metastasis and a very poor prognosis. In search for compounds that may reduce the tumorigenic potential of gliomas/glioblastomas honokiol attracted our attention. Honokiol, purified from the bark of traditional Chinese herbal medicine Magnolia species, is beneficial in vitro and in animal models via a variety of pharmacological effects, including anti-inflammatory, anti-angiogenetic, anti-arrhythmic and antioxidant activities, as well as anti-proliferative and proapoptotic effects in a wide range of human cancer cells. However, its effects on glioma cells are unknown. Here, we used different concentrations of honokiol in treating U251 and U-87 MG human glioma/glioblastoma cells in cell culture. Results showed that honokiol inhibited glioma cell viability and colony formation and promoted apoptosis. It also inhibited glioma cell migration/proliferation and invasion. In addition, honokiol promoted apoptosis and reduced Bcl-2 expression, accompanied by increase in Bax expression. Honokiol reduced expression of EGFR, CD133 and Nestin. Moreover, honokiol inhibited the activation of both AKT and ERK signaling pathways, increased active caspase-3 level and reduced phosphorylation of STAT3. U-87 MG xenografts in nude mice and in immunotolerant zebrafish yolk sac showed that honokiol inhibits tumor growth and metastasis. Altogether, results indicate that honokiol reduces tumorigenic potentials, suggesting hopes for honokiol to be useful in the clinical management of glioma/glioblastoma.Keywords
Funding Information
- National Natural Science Foundation of China (81471279, 81171138)
This publication has 51 references indexed in Scilit:
- Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancerOncogene, 2011
- Targeting PI3K signalling in cancer: opportunities, challenges and limitationsNature Reviews Cancer, 2009
- Honokiol, a Multifunctional Antiangiogenic and Antitumor AgentAntioxidants and Redox Signaling, 2009
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Nuclear factor-κB in cancer development and progressionNature, 2006
- Targeting the mitogen-activated protein kinase cascade to treat cancerNature Reviews Cancer, 2004
- Expression of antisense bcl‐2 cDNA abolishes tumorigenicity and enhances chemosensitivity of human malignant glioma cellsJournal of Neuroscience Research, 2003
- Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cellsGenes & Development, 2003
- Novel treatments and therapies in development for pancreatic cancerExpert Opinion on Investigational Drugs, 2002